
Nymox Pharmaceutical Corporation NYMX
Annual report 2024
added 03-07-2026
Nymox Pharmaceutical Corporation P/S Ratio 2011-2026 | NYMX
Annual P/S Ratio Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 38.5 K | 1.7 K | 439 | 759 | 480 | 31.3 | 4.66 | 57.9 | 71.8 | 83.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.5 K | 4.66 | 4.22 K |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
105 | $ 0.79 | -1.15 % | $ 4.31 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
AbCellera Biologics
ABCL
|
12.8 | $ 3.49 | 0.58 % | $ 1.04 B | ||
|
Frequency Therapeutics
FREQ
|
12.6 | - | - | $ 528 M | ||
|
argenx SE
ARGX
|
311 | $ 700.45 | -1.19 % | $ 25 B | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Alterity Therapeutics Limited
ATHE
|
131 | $ 3.6 | 1.41 % | $ 8.66 B | ||
|
Grifols, S.A.
GRFS
|
1.71 | $ 7.81 | -2.01 % | $ 6.83 B | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
947 | $ 225.98 | -1.32 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
BioCardia
BCDA
|
18.6 | $ 1.26 | -0.79 % | $ 26.7 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Anika Therapeutics
ANIK
|
2.24 | $ 14.2 | -0.7 % | $ 208 M | ||
|
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
Athersys
ATHX
|
253 | - | 3.77 % | $ 22.4 M | ||
|
BioNTech SE
BNTX
|
35.7 | $ 91.19 | 1.21 % | $ 27.2 B | ||
|
Aptinyx
APTX
|
204 | - | -39.0 % | $ 4.57 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.37 K | $ 1.44 | -1.37 % | $ 367 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
2.65 | $ 6.68 | -4.57 % | $ 183 M | ||
|
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | ||
|
AVEO Pharmaceuticals
AVEO
|
2.32 | - | - | $ 521 M | ||
|
Burford Capital Limited
BUR
|
6.35 | $ 7.92 | 1.67 % | $ 1.31 B | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
0.237 | $ 2.54 | -5.22 % | $ 16 M | ||
|
Certara
CERT
|
2.57 | $ 6.67 | 1.6 % | $ 1.07 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
759 | $ 3.6 | -4.0 % | $ 7.83 B | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
Aravive
ARAV
|
6.61 | - | -13.39 % | $ 1.45 M |